<DOC>
	<DOC>NCT00452725</DOC>
	<brief_summary>1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome</brief_summary>
	<brief_title>Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Noonan Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Children and adolescents with Noonan's syndrome with a height &lt; 2 SD and no progressive cardiopathy Age &lt; 3 years Height ≥ 2 SD The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>